dimethyl fumarate (Rx)

Brand and Other Names:Tecfidera, BG-12

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule, delayed-release

  • 120mg
  • 240mg

Multiple Sclerosis

Indicated for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

120 mg PO BID initially; after 7 days, increase to maintenance dose of 240 mg BID

Consider temporary dose reductions to 120 mg BID for individuals who do not tolerate the maintenance dose

Within 4 weeks, resume the recommended dose of 240 mg BID

Consider discontinuation in patients who are unable to tolerate the recommended maintenance dose

Dosing Considerations

Recent CBC (ie, within 6 months) recommended before initiation to identify patients with pre-existing low lymphocyte counts

Consider withholding treatment in patients with serious infections until the infection(s) resolved

Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating treatment

Friedreich's Ataxia (Orphan)

Orphan designation for treatment of Friedreich's ataxia

Orphan sponsor

  • Gino Cortopassi; 608 12th Street; Davis, CA 95616

Safety and efficacy not established

Next:

Adverse Effects

>10%

Flushing (40%)

Abdominal pain (18%)

Diarrhea (14%)

Nausea (12%)

1-10%

Vomiting (9%)

Pruritus (8%)

Rash (8%)

Albumin in urine (6%)

Erythema (5%)

Dyspepsia (5%)

Increased AST (4%)

Lymphopenia (2%)

Frequency Not Defined

Transient eosinophilia

Hepatobiliary disorders including liver function abnormalities (elevations in transaminases greater than or equal to 3 times ULN with concomitant elevations in total bilirubin > 2 times ULN)

Postmarketing Reports

Rhinorrhea

Alopecia

Herpes zoster and other serious opportunistic infections

Previous
Next:

Warnings

Contraindications

Hypersensitivity to drug or components

Cautions

May cause lymphopenia; obtain a CBC including lymphocyte count before initiating therapy, after 6 months, and q6-12 months thereafter, and as clinically indicated; consider treatment interruption with lymphocyte counts <0.5 x 10^9/L persisting for >6 months; continue to obtain lymphocyte counts until their recovery if drug is discontinued or interrupted due to lymphopenia; consider withholding treatment from patients with serious infections until resolution; decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances

Flushing (eg, warmth, redness, itching, and/or burning sensation) may occur; flushing symptoms generally may happen soon after initiating treatment and improve or resolve over time; in the majority of patients experiencing flushing, it is mild or moderate in severity

Progressive multifocal leukoencephalopathy (PML) resulting in death, in the postmarketing setting have occurred; withhold therapy at first sign or symptom suggestive of PML; perform appropriate diagnostic evaluation; cases have occurred predominantly in patients with lymphocyte counts <0.8x10^9/L persisting for more than 6 months; role of lymphopenia in PML cases uncertain

Do not restart therapy if anaphylaxis or angioedema occur

Clinically significant cases of liver injury reported; onset ranged from a few days to several months after treatment initiation; elevated hepatic transaminases (most not >3 x ULN) were observed during controlled trials and resolved upon treatment discontinuation; discontinue drug if clinically significant signs and symptoms of liver injury occur; obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior to treatment and during treatment, as clinically indicated; discontinue treatment if clinically significant liver injury induced by drug suspected

Opportunistic infections

  • Serious cases of herpes zoster have occurred, including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster meningomyelitis
  • Monitor patients for signs and symptoms of herpes zoster; if herpes zoster occurs, appropriate treatment should be administered; consider withholding treatment in patients with herpes zoster or other serious infections until infection has resolved
  • Other serious opportunistic infections have occurred, including cases of serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections; these infections have been reported in patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC; these infections have affected the brain, meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and ear
  • Patients with symptoms and signs consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment

Lymphopenia

  • Drug may decrease lymphocyte counts; drug has not been studied in patients with pre­existing low lymphocyte counts
  • Obtain a CBC, including lymphocyte count, before initiating treatment with drug, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated
  • Consider interruption of drug in patients with lymphocyte counts less than 0.5 x 109/L persisting for more than six months; given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if drug is discontinued or interrupted due to lymphopenia
  • Consider withholding treatment from patients with serious infections until resolution; decisions about whether or not to restart therapy should be individualized based on clinical circumstances
Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no adequate data on developmental risk associated with use in pregnant women; in animals, adverse effects on offspring survival, growth, sexual maturation, and neurobehavioral function were observed when dimethyl fumarate (DMF) was administered during pregnancy and lactation at clinically relevant doses

Pregnancy registry

  • Monitors pregnancy outcomes in women exposed to dimethyl fumarate during pregnancy; encourage patients to enroll by calling 1-866-810-1462 or visiting www.tecfiderapregnancyregistry.com

Lactation

There are no data on presence of DMF or MMF in human milk; effects on breastfed infant and on milk production are unknown

The developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for drug and any potential adverse effects on breastfed infant from drug or from underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Exact mechanism is unknown

Methyl ester of fumaric acid that elicits immunomodulatory effects

Dimethyl fumarate and the metabolite (monomethyl fumarate [MMF]) activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, a transcription factor encoded by the NFE2L2 gene

The Nrf2 antioxidant response pathway is a cellular defense against oxidative stress

MMF has been identified as a nicotinic acid receptor agonist in vitro

Absorption

Peak Plasma Time: 2-2.5 hr (MMF)

Peak Plasma Concentration: 1.87 mg/L (MMF)

AUC: 8.21 mg•h/L (MMF)

High-fat, high-calorie meal did not affect AUC, but decreased Cmax by 40% and delayed Tmax to 5.5 hr (flushing decreased ~25%)

Distribution

Protein Bound: 27-45% (MMF)

Vd: 53-73 L

Metabolism

Metabolized rapidly by presystemic hydrolysis by esterases in GI tract, blood, and tissues (before it reaches systemic circulation) and is converted to its active metabolite, monomethyl fumarate (MMF)

Further metabolism of MMF occurs via tricarboxylic acid (TCA) cycle with no involvement of CYP450 system

Metabolites: MMF, fumaric acid, citric acid, and glucose

Elimination

Excretion: 60% by exhalation of CO2; 16% renal; 1% feces

Previous
Next:

Administration

Oral Administration

Swallow capsule whole and intact; do not chew, crush, or sprinkle on food

May take with or without food

Administration with food may reduce incidence of flushing by ~25%

Alternatively, administration of nonenteric coated aspirin (up to a dose of 325 mg) 30 minutes before each dose may reduce the incidence or severity of flushing

Storage

Capsules: Store at 15-30ºC (59-86ºF); protect the capsules from light; store in original container

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Tecfidera oral
-
240 mg capsule
Tecfidera oral
-
120 mg capsule
Tecfidera oral
-
120 mg (14)- 240 mg (46) capsule
dimethyl fumarate oral
-
120 mg capsule
dimethyl fumarate oral
-
240 mg capsule
dimethyl fumarate oral
-
120 mg capsule
dimethyl fumarate oral
-
240 mg capsule
dimethyl fumarate oral
-
240 mg capsule
dimethyl fumarate oral
-
120 mg capsule
dimethyl fumarate oral
-
120 mg capsule
dimethyl fumarate oral
-
120 mg (14)- 240 mg (46) capsule
dimethyl fumarate oral
-
240 mg capsule
dimethyl fumarate oral
-
240 mg capsule
dimethyl fumarate oral
-
120 mg capsule

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.